NASDAQ:AXDX Investor Notice: Investigation over Possible Securities Laws Violations by Accelerate Diagnostics, Inc.
An investigation for investors in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) shares over potential securities laws violations by Accelerate Diagnostics, Inc. was announced.
San Diego, CA -- (SBWire) -- 11/09/2022 --Accelerate Diagnostics, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Accelerate Diagnostics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Tucson, AZ based Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. On October 21, 2022, after market hours, Accelerate Diagnostics, Inc. filed a current report with the SEC which announced that, pursuant to discussions with the U.S. Food and Drug Administration ("FDA"), the Company would, among other things: "(i) discontinu[e] the U.S. marketing and distribution of [its Accelerate Arc system and related BC Kit (collectively, the "Accelerate Arc Products")] for positive blood culture processing and subsequent identification by mass spectrometry for diagnostic use; (ii) remov[e] and/or correct all U.S. promotional information within the Company's control (e.g., website, labeling, social media, sales associate information, or other promotional material) regarding the diagnostic use of the Accelerate Arc Products as Class I devices or as devices intended as positive blood culture processing devices for subsequent identification of microorganisms by mass spectrometry; and (iii) revis[e]/remov[e] the Company's registration and listing of the Accelerate Arc Products as Class I devices."
Shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) declined to 0.89 per share on October 24, 2022.
Those who purchased shares of Accelerate Diagnostics, Inc. (NASDAQ: AXDX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
View this press release online at: http://rwire.com/1366124